1. Home
  2. ASIX vs CTNM Comparison

ASIX vs CTNM Comparison

Compare ASIX & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AdvanSix Inc.

ASIX

AdvanSix Inc.

N/A

Current Price

$18.68

Market Cap

527.0M

Sector

Industrials

ML Signal

N/A

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

N/A

Current Price

$13.37

Market Cap

507.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ASIX
CTNM
Founded
2016
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
527.0M
507.0M
IPO Year
2016
2024

Fundamental Metrics

Financial Performance
Metric
ASIX
CTNM
Price
$18.68
$13.37
Analyst Decision
Buy
Buy
Analyst Count
2
5
Target Price
$26.00
$19.80
AVG Volume (30 Days)
356.6K
174.8K
Earning Date
05-22-2026
06-08-2026
Dividend Yield
3.26%
N/A
EPS Growth
11.11
0.46
EPS
1.80
N/A
Revenue
$1,684,625,000.00
N/A
Revenue This Year
$3.53
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.93
N/A
Revenue Growth
45.49
N/A
52 Week Low
$14.10
$3.35
52 Week High
$25.53
$16.33

Technical Indicators

Market Signals
Indicator
ASIX
CTNM
Relative Strength Index (RSI) 52.74 41.08
Support Level $17.54 $10.17
Resistance Level $19.68 $16.17
Average True Range (ATR) 1.18 0.98
MACD 0.02 -0.36
Stochastic Oscillator 38.07 5.43

Price Performance

Historical Comparison
ASIX
CTNM

About ASIX AdvanSix Inc.

AdvanSix Inc is a diversified chemistry company playing a critical role in international supply chains, innovating and delivering essential products for customers across a wide variety of end markets and applications that touch people's lives, including building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, and electronics. The company's key products include Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates. The majority of sales are from Plant Nutrients products. The company operates in the United States and internationally, with the majority of revenue coming from the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: